BIG PICTURE BIO LIMITED

Based in the UK, BIG PICTURE BIO LIMITED, operates as a provider of software and research services that model and predict drug combinations for cancer therapy development and clinical trial evaluation. Based in London, the UK and founded in 2026, BIG PICTURE BIO LIMITED provides innovative solutions in the healthcare sector. This funding is part of a larger GBP 2. 2 mn pre-seed and Grant funding round.

The company will use the funding to advance its first designed drug combinations from computational design into wet-lab validation. BIG PICTURE BIO LIMITED specializes in predicting novel synergistic drug combinations for cancer therapy. Utilizing advanced mechanistic models, the company identifies effective drug pairings from a database of over 60 billion combinations to combat tumor resistance. Their proprietary algorithms analyze complex interactions within cancer biology, ensuring optimal therapeutic environments.

The services target pharmaceutical companies, biotech firms, and healthcare investors, facilitating successful combination trials across diverse cancer patient populations globally. BIG PICTURE BIO LIMITED's revenue model is based on strategic partnerships and collaborations within the pharmaceutical and biotech industries. Clients engage with the firm to access its predictive platform, which offers quick assessments of potential drug combinations. Service agreements may include fee-for-service contracts for specific projects and ongoing partnerships for comprehensive drug development efforts.

The firm also provides consulting services to guide customers in effective drug pairing strategies, enhancing the efficiency of cancer treatment strategies. The company plans to advance its first designed drug combinations from computational design into wet-lab validation, utilizing the recent funding to support this initiative.